000			01151nam a2200193Ia 4500
003			MX-MdCICY
005			20250625162417.0
040			_cCICY
090			_aB-18722
245	1	0	_aThirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
490	0		_vJ. Med. Chem, 63, p.12460-12484, 2020
520	3		_aIt is now 30 years since the first report of a potent zincdependent histone deacetylase (HDAC)inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy while many others are in clinical development for oncology as well as other therapeutic indications. This Perspective reviews the biological and medicinal chemistry advances over the past 3 decades with an emphasis on the design of selective inhibitors that discriminate between the 11 human HDAC isoforms.
700	1	2	_aHo, Terence C. S.
700	1	2	_aChan, Alex H. Y.
700	1	2	_aGanesan, A.
856	4	0	_uhttps://drive.google.com/file/d/1G1JalsFr3YBxBV-Tfd-3Ewr5R8ZHMwph/view?usp=drivesdk _zPara ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx
942			_2Loc _cREF1
008			250602s9999 xx |||||s2 |||| ||und|d
999			_c52868 _d52868